Keith Blundy, CEO of Storm Therapeutics, discusses the company’s founding and upcoming milestones. He talks to Scrip’s John Hodgson about STORM’s RNA pipeline, its platform technology and business model.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?